Company: WHWK
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023932
Chunk: 458

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 458
---
 treatments. The CODM assesses performance for the Company's single operating segment and decides how to allocate resources primarily based on research and development expenses incurred, which is a component of the Company's consolidated net income (loss) as reported on the consolidated statement of operations and comprehensive income (loss). The measure of segment assets is reported on the balance sheet as total consolidated assets. Further, segment depreciation expense and segment asset additions are consistent with consolidated amounts reported within the consolidated statement of cash flows given the Company's operations are aggregated within a single reportable segment. The Company's revenues relate to sales of FYARRO, which was divested as of March 25, 2025. All the assets and operations of the Company’s sole operating and reportable segment are located in the United States.Significant segment expenses which are regularly reported to the CODM for purposes of making decisions regarding the allocation of resources are included within the table below and are reconciled to consolidated net loss (in thousands): 

23

Three Months Ended March 31,20252024Product sales, net$7,145 $5,353 Less:FYARRO - research and development expenses5,313 10,271 FYARRO - contract manufacturing expenses— 3,322 ADC assets - contract manufacturing3,475 — FYARRO - commercial and marketing expenses294 601 Finance and accounting expenses (1)3,216 3,692 Legal expenses2,587 1,258 Other segment items (2)7,478 5,780 Interest income(791)(1,282)Gain on sale of business(87,443)— Net loss$73,016 $(18,289)(1) Finance and accounting expenses primarily include shared-based compensation, insurance, salaries and wages, and other outside consulting services.(2) Other segment items primarily include other SGA departmental expenses, cost of sales, interest expense, and foreign exchange loss.

24

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (“Quarterly Report”) contains express or implied forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe